ArticleFrontiers in medicine2026
Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bockenheimer disease is a rare subtype of venous malformations that involves all tissue planes of an upper extremity. This condition progresses throughout life and may cause pain, swelling, hematologic complications, and loss of function. Management for Bockenheimer disease remains challenging. Case presentation: This study presents a case of a 14-year-old girl with late-stage Bockenheimer disease complicated by severe anemia and coagulation disorder. The patient underwent anticoagulation therapy initially, followed by sclerotherapy combined with local suture ligation twice, and received anticoagulants and molecular targeted medication on maintenance post-discharge. Follow-up after 9 months demonstrated a marked improvement in the general condition and significant volume reduction in the affected limb. Laboratory test results revealed recovery of anemia and well-controlled coagulopathy. Complications included contracture in the left elbow. Conclusion: Management for Bockenheimer disease requires multimodal therapy, including sclerotherapy, resection, molecular targeted medication, and anticoagulation throughout the entire process. Prompt intervention at an early stage is crucial to the prognosis. Close attention should be paid to the hematologic profiles, especially during the perioperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.